GlassScriptPhysician profile
Mohammed S Ahmad
NPI 1104030865
$4,034.38
in general payments reported to CMS, 2019-2025
30 companies · $285 in 2025
The $285 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $459 · 2020: $160 · 2021: $549 · 2022: $679 · 2023: $848 · 2024: $1,055 · 2025: $285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,120 · Education: $67.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,119.94 |
| Education | $67.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,011.11 | 2019-2025 | Farxiga, Lokelma, Evusheld |
| Aurinia Pharma U.S., INC. | $506.25 | 2021-2024 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $282.52 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $266.36 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $215.86 | 2021-2024 | Jynarque |
| Glaxosmithkline, LLC. | $207.35 | 2022-2023 | Benlysta |
| Mallinckrodt Hospital Products INC. | $203.91 | 2020-2022 | |
| Veloxis Pharmaceuticals, INC. | $143.91 | 2019-2024 | Envarsus |
| Amgen INC. | $134.49 | 2019-2024 | Tavneos |
| Cormedix INC. | $132.82 | 2024 | Defencath |
| Travere Therapeutics, INC. | $123.89 | 2023-2024 | |
| Vifor Pharma, INC. | $115.62 | 2020-2024 | Veltassa |
| Novo Nordisk INC | $92.52 | 2024-2025 | Rivfloza, Ozempic, Rybelsus |
| Horizon Therapeutics Plc | $77.14 | 2019-2021 | |
| Ultragenyx Pharmaceutical INC. | $61.91 | 2022-2024 | Crysvita |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $60.15 | 2024 | Jardiance |
| Mallinckrodt Enterprises LLC | $58.43 | 2019 | |
| Fresenius USA Marketing, INC. | $54.06 | 2023-2024 | |
| Nxstage Medical, INC. | $51.48 | 2019 | |
| Janssen Pharmaceuticals, INC | $33.28 | 2022 | |
| Livanova USA, INC. | $24.35 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.83 | 2024 | Jardiance |
| Intercept Pharmaceuticals, INC. | $21.25 | 2022 | |
| Medtronic, INC. | $20.66 | 2025 | Inceptiv |
| Merck Sharp & Dohme LLC | $19.81 | 2019 | |
| Akebia Therapeutics INC | $19.27 | 2025 | Vafseo |
| Amicus Therapeutics, INC. | $18.29 | 2023 | Galafold |
| Alexion Pharmaceuticals, INC. | $18.15 | 2022 | |
| Calliditas Therapeutics US INC. | $17.97 | 2022 | |
| Ani Pharmaceuticals, INC. | $17.74 | 2023 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Ahmad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.